WASHINGTON (Reuters)—The Congressional Budget Office on Wednesday said that repealing the individual mandate for health insurance would reduce the federal budget deficit less than first forecast as it readied a revised analysis of a policy shift favored by Republicans. The CBO, the nonpartisan budget-scoring agency, said in a statement on its website that eliminating the…
Bisphosphonates May Limit Fracture Risk in Users of Oral Glucocorticoids
NEW YORK (Reuters Health)—Early oral bisphosphonate use is associated with a lower risk of fractures among oral-glucocorticoid users, researchers from Canada report. Bisphosphonates are commonly used for glucocorticoid-induced osteoporosis, but their efficacy has been established only in primary osteoporosis, where the mechanism of action of bone loss differs from that seen with glucocorticoid use. Dr….
Maine Governor Will Not Expand Medicaid, Ignoring Voters
(Reuters)—Maine Republican Governor Paul LePage said on Wednesday he will not expand the state’s Medicaid program under Obamacare, ignoring a ballot initiative widely backed by voters, calling it “ruinous” for the state’s budget. Maine looked set to become the first state in the nation to expand Medicaid by popular vote. About 60% of voters in…
Ex-Pharma Exec Azar Is Top Choice to Run U.S. Health Agency
WASHINGTON (Reuters)—Alex Azar, a former pharmaceutical company executive, is U.S. President Donald Trump’s top pick to run the Department of Health and Human Services, two sources with knowledge of the confidential process said on condition of anonymity on Wednesday. Azar served at Eli Lilly for a decade, including five years as president of its U.S….
Kentucky Accuses Endo of Contributing to Opioid Epidemic
(Reuters)—Kentucky accused units of Endo International Plc. on Monday of contributing to drug overdoses by deceptively marketing its painkiller Opana ER, in the latest lawsuit by state or local governments against the drugmaker amid an opioid epidemic. Kentucky Attorney General Steve Beshear said the lawsuit would seek to hold Endo responsible for illegally building a…
J&J’s Stelara Shows Promise Against Lupus in Study
(Reuters)—Johnson & Johnson’s blockbuster psoriasis drug ustekinumab (Stelara) led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a midstage clinical trial, according to data released on Nov. 4. Ustekinumab is already approved for psoriasis, psoriatic arthritis and Crohn’s disease and had third-quarter sales of $1.12 billion….
Insurers Step Up Pitch for Obamacare as Government Slashes its Effort
NEW YORK (Reuters)—President Donald Trump’s 90% cut to Obamacare advertising has U.S. health insurers in many states digging deeper into their pockets to get the word out about 2018 enrollment, which opened last week. Independence Blue Cross, a health insurer in Pennsylvania, has commissioned a tractor-trailer truck to bring insurance consultants out to shopping centers…
Researchers Examine Lifetime Risk of Total Hip Replacements
Total hip replacement (THR) surgery is an effective way to reduce pain and improve function in people with advanced hip osteoarthritis (OA). In light of aging populations, there’s a need to use contemporary, population-level data to plan for future service provision. In a study designed to compare THR data across countries, researchers demonstrated a significant increase in the overall use of and lifetime risk for THR from 2003 to 2013. Women consistently had a higher lifetime risk of surgery than men in all five countries studied, whereas men in all five countries demonstrated a significant increase in lifetime risk for THR over time…
U.S. Congress to Hold Hearing on Allergan Tribal Patent Deal
(Reuters)—A U.S. House of Representatives subcommittee on Thursday called a November 7 hearing on the legitimacy of an agreement between drugmaker Allergan Plc and a Native American tribe intended to shield patents from administrative review. The House Judiciary Committee’s subcommittee on intellectual property, chaired by Republican Representative Darrell Issa of California, said in a statement…
AmerisourceBergen Expects Tumbling Generic Drug Prices to Settle
(Reuters)—AmerisourceBergen Corp said it expects stubbornly low generic drug prices, which have plagued drugmakers and wholesalers, to not deteriorate further next year, and brushed off concerns about Amazon’s possible entry into the industry. The drug distributor ended its fiscal year with a quarterly loss as it set aside $575 million for legal costs for a…
- « Previous Page
- 1
- …
- 167
- 168
- 169
- 170
- 171
- …
- 310
- Next Page »